- Home
- INVA vs GRDN Comparison
INVA vs GRDN Comparison
Compare INVA & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVA | GRDN |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | United States |
| Employees | N/A | 3400 |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | INVA | GRDN |
|---|---|---|
| Price | $22.39 | $33.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $36.50 | $33.33 |
| AVG Volume (30 Days) | ★ 730.3K | 141.9K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 816.67 | N/A |
| EPS | ★ 3.30 | N/A |
| Revenue | ★ $217,217,000.00 | N/A |
| Revenue This Year | $8.78 | $19.50 |
| Revenue Next Year | $11.99 | N/A |
| P/E Ratio | ★ $6.68 | $117.77 |
| Revenue Growth | ★ 62.63 | N/A |
| 52 Week Low | $16.52 | $18.37 |
| 52 Week High | $25.15 | $37.43 |
Technical Indicators
Market Signals| Indicator | INVA | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 55.77 |
| Support Level | $19.16 | $27.70 |
| Resistance Level | $22.76 | $34.98 |
| Average True Range (ATR) | 0.71 | 1.36 |
| MACD | -0.23 | -0.13 |
| Stochastic Oscillator | 18.46 | 69.44 |
Price Performance
Historical ComparisonAbout INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
About GRDN Guardian Pharmacy Services Inc.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.